HTR3B
MOLECULAR TARGET5-hydroxytryptamine receptor 3B
HTR3B (5-hydroxytryptamine receptor 3B) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting HTR3B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Ondansetron | 3.66 | 38 |
| 2 | Quipazine | 3.09 | 21 |
| 3 | Metoclopramide | 3.04 | 20 |
| 4 | Mianserin | 1.61 | 4 |
| 5 | Mescaline Hallucinogenic alkaloid isolated from | 1.10 | 2 |
| 6 | Pergolide | 1.10 | 2 |
| 7 | Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent | 0.69 | 1 |
| 8 | Aripiprazole | 0.69 | 1 |
| 9 | Cyproheptadine | 0.69 | 1 |
| 10 | Nortriptyline | 0.69 | 1 |
| 11 | Sumatriptan | 0.69 | 1 |
About HTR3B as a Drug Target
HTR3B (5-hydroxytryptamine receptor 3B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented HTR3B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
HTR3B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.